The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers
Background The macrolide antibiotics clarithromycin and erythromycin may potentiate
calcium-channel blockers by inhibiting cytochrome P450 isoenzyme 3A4. However, this …
calcium-channel blockers by inhibiting cytochrome P450 isoenzyme 3A4. However, this …
Calcium-channel blocker–clarithromycin drug interactions and acute kidney injury
S Gandhi, JL Fleet, DG Bailey, E McArthur, R Wald… - Jama, 2013 - jamanetwork.com
Importance Calcium-channel blockers are metabolized by the cytochrome P450 3A4
(CYP3A4; EC 1.14. 13.97) enzyme. Blood concentrations of these drugs may rise to harmful …
(CYP3A4; EC 1.14. 13.97) enzyme. Blood concentrations of these drugs may rise to harmful …
Estimated cardiac risk associated with macrolides and fluoroquinolones decreases substantially when adjusting for patient characteristics and comorbidities
LA Polgreen, BN Riedle, JE Cavanaugh… - Journal of the …, 2018 - Am Heart Assoc
Background Some studies have found that antimicrobials, especially macrolides, increase
the risk of cardiovascular death. We investigated potential cardiac‐related events associated …
the risk of cardiovascular death. We investigated potential cardiac‐related events associated …
Macrolide antibiotics and the risk of ventricular arrhythmia in older adults
Background: Many respiratory tract infections are treated with macrolide antibiotics.
Regulatory agencies warn that these antibiotics increase the risk of ventricular arrhythmia …
Regulatory agencies warn that these antibiotics increase the risk of ventricular arrhythmia …
Cardiac risks associated with antibiotics: azithromycin and levofloxacin
Introduction: Azithromycin and levofloxacin have been shown to be efficacious in treating
infections. The adverse drug events associated with azithromycin and levofloxacin were …
infections. The adverse drug events associated with azithromycin and levofloxacin were …
The role of macrolide antibiotics in increasing cardiovascular risk
YJ Cheng, XY Nie, XM Chen, XX Lin, K Tang… - Journal of the American …, 2015 - jacc.org
Background: Large cohort studies provide conflicting evidence regarding the potential for
oral macrolide antibiotics to increase the risk of serious cardiac events. Objectives: This …
oral macrolide antibiotics to increase the risk of serious cardiac events. Objectives: This …
Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides
Studies reporting an increased risk for cardiac toxicities with macrolide antibiotics have
raised concern regarding their cardiovascular safety. We sought to assess the cardiac safety …
raised concern regarding their cardiovascular safety. We sought to assess the cardiac safety …
[HTML][HTML] Cardiovascular risks with azithromycin and other antibacterial drugs
AD Mosholder, J Mathew, JJ Alexander… - … England Journal of …, 2013 - Mass Medical Soc
The FDA recently approved labeling changes advising against the use of azithromycin in
patients with known cardiovascular risk factors such as QT-interval prolongation …
patients with known cardiovascular risk factors such as QT-interval prolongation …
[HTML][HTML] Azithromycin and the risk of cardiovascular death
WA Ray, KT Murray, K Hall, PG Arbogast… - New England Journal …, 2012 - Mass Medical Soc
Background Although several macrolide antibiotics are proarrhythmic and associated with
an increased risk of sudden cardiac death, azithromycin is thought to have minimal …
an increased risk of sudden cardiac death, azithromycin is thought to have minimal …
The cardiovascular safety of azithromycin
DN Juurlink - CMAJ, 2014 - Can Med Assoc
The clinically important question, however, is whether azithromycin itself causes
cardiovascu lar death or is simply a marker of increased risk. Patients who are sick enough …
cardiovascu lar death or is simply a marker of increased risk. Patients who are sick enough …
